Din Ryan S, Tsiaras William G, Li David G, Mostaghimi Arash
J Drugs Dermatol. 2018 Oct 1;17(10):1058-1060.
Pyoderma gangrenosum (PG) is a neutrophilic dermatosis commonly treated with steroid immunosuppression. The utility of dapsone as a non-immunosuppressive treatment for PG has been reported in case reports and series. We sought to evaluate the response and tolerability of concurrent systemic dapsone therapy for treating PG.
We reviewed PG patients treated with systemic dapsone at Massachusetts General Hospital and Brigham and Women's Hospital from 2000-2015. A treatment episode was defined as a minimum of 4 weeks of dapsone therapy with a documented response of complete, partial, or no improvement in wound healing.
27 patients treated with systemic dapsone met inclusion criteria. 15.6% of treatment episodes demonstrated a response of complete healing, 81.3% of treatment episodes demonstrated a response of partial improvement, and 1 patient (3.1%) demonstrated no response. 9 patients (33.3%) had documented side effects of varying severity, with one (3.7%) requiring cessation of dapsone therapy.
Systemic dapsone therapy may represent an effective and tolerable non-immunosuppressive adjuvant treatment for PG wound healing. J Drugs Dermatol. 2018;17(10):1058-1060.
坏疽性脓皮病（PG）是一种嗜中性皮病，通常采用类固醇免疫抑制疗法进行治疗。个案报告及系列研究中已报道了氨苯砜作为PG的非免疫抑制治疗方法的效用。我们旨在评估氨苯砜全身联合治疗PG的疗效和耐受性。
我们回顾了2000年至2015年在马萨诸塞州总医院和布莱根妇女医院接受氨苯砜全身治疗的PG患者。一个治疗疗程定义为至少4周的氨苯砜治疗，并有记录显示伤口愈合完全、部分改善或无改善。
27例接受氨苯砜全身治疗的患者符合纳入标准。15.6%的治疗疗程显示完全愈合，81.3%的治疗疗程显示部分改善，1例患者（3.1%）无改善。9例患者（33.3%）有不同程度的副作用记录，其中1例（3.7%）需要停止氨苯砜治疗。
氨苯砜全身治疗可能是一种有效且耐受性良好的PG伤口愈合非免疫抑制辅助治疗方法。《药物皮肤病学杂志》。2018年；17（10）：1058 - 1060。
